Hepatic Methotrexate-associated Lymphoproliferative Disease: a Case Report and Literature Review

Overview

Journal Surg Case Rep

Specialty General Surgery

Date 2024 Nov 14

PMID 39542926

Authors

Shinya Sakamoto

Motoyasu Tabuchi

Rika Yoshimatsu

Manabu Matsumoto

Jun Iwata

Takehiro Okabayashi

Affiliations

Soon will be listed here.

Abstract

Background: Methotrexate-associated lymphoproliferative disease (MTX-LPD) is a rare and life-threatening complication of MTX administration. MTX-LPD features more extranodal lesions than malignant lymphoma; however, the liver is an extremely rare organ that develops LPD. Herein, we present a case of hepatic MTX-LPD treated with surgical resection. We also reviewed the literature on hepatic MTX-LPD.

Case Presentation: A 66-year-old man with a history of rheumatoid arthritis (RA) was admitted to our department for the treatment of hepatic solitary liver tumor. The patient had been receiving MTX (14 mg/week) for RA for 6 years. MTX was withdrawn and salazosulfapyridine was prescribed 3 weeks prior to admission because of mediastinal MTX-LPD. Abdominal contrast-enhanced computed tomography showed a slightly ring-like enhanced hypovascularized mass (80 mm) in the lateral section of the liver. Carbohydrate antigen 19-9 (78.1 U/mL) level was elevated. No evidence was observed on esophagogastroduodenoscopy or colonoscopy. The tumor was suspected to be an intrahepatic cholangiocarcinoma. The patient underwent hepatic lateral sectionectomy and lymphadenectomy. Pathological examination revealed that the hepatic mass was coagulative necrosis of the CD20-positive B-cell lymphocytes. These histological findings were similar to those of rapid necrotic lymphoma. MTX-LPD is known to spontaneously regress after withdrawing MTX, and the patient was diagnosed with hepatic MTX-LPD.

Conclusions: MTX-LPD can occur in the liver. Clinician should suspect hepatic MTX-LPD when a liver mass is detected in patient who had been treating with MTX for RA.

References

Miyamoto Y, Kawasoe C, Ito K, Oguri N, Murashima T, Kamibeppu T . Hepatic and lung methotrexate-associated polymorphic lymphoproliferative disorders arising during postoperative follow-up of renal cell carcinoma: a case report. J Med Case Rep. 2023; 17(1):524. PMC: 10740260. DOI: 10.1186/s13256-023-04288-z. View

Park J, Lee K, Choi H, Ahn S, You M . Methotrexate-associated primary hepatic lymphoma and cranial neuropathy in a patient with rheumatoid arthritis: A case report with clinical follow-up over a 7-year period. Medicine (Baltimore). 2019; 98(17):e14997. PMC: 6831240. DOI: 10.1097/MD.0000000000014997. View

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

Johnston A, Gudjonsson J, Sigmundsdottir H, Ludviksson B, Valdimarsson H . The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005; 114(2):154-63. DOI: 10.1016/j.clim.2004.09.001. View

Salloum E, Cooper D, Howe G, Lacy J, Tallini G, Crouch J . Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996; 14(6):1943-9. DOI: 10.1200/JCO.1996.14.6.1943. View

Kawahara A, Tsukada J, Yamaguchi T, Katsuragi T, Higashi T . Reversible methotrexate-associated lymphoma of the liver in rheumatoid arthritis: a unique case of primary hepatic lymphoma. Biomark Res. 2015; 3:10. PMC: 4426646. DOI: 10.1186/s40364-015-0035-2. View

Matsumoto R, Numata K, Doba N, Hara K, Chuma M, Fukuda H . A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder. J Med Ultrason (2001). 2016; 43(4):545-51. DOI: 10.1007/s10396-016-0740-y. View

Morikawa S, Morita A, Fujimitsu R, Kuroki Y, Urakawa H, Shinagawa Y . MR Imaging of a Methotrexate-associated Diffuse Large B-cell Lymphoma in the Liver that Regressed without Treatment. Magn Reson Med Sci. 2016; 15(3):249-50. PMC: 5608119. DOI: 10.2463/mrms.ci.2015-0061. View

Saito S, Takeuchi T . Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. J Clin Exp Hematop. 2019; 59(4):145-155. PMC: 6954173. DOI: 10.3960/jslrt.19028. View

10.

Mizusawa T, Kamimura K, Sato H, Suda T, Fukunari H, Hasegawa G . Methotrexate-related lymphoproliferative disorders in the liver: Case presentation and mini-review. World J Clin Cases. 2019; 7(21):3553-3561. PMC: 6854407. DOI: 10.12998/wjcc.v7.i21.3553. View

11.

Fujita T, Tanabe M, Iida E, Okimoto T, Matsunaga N . Multi-modality imaging findings of methotrexate-related Epstein-Barr virus-associated hepatic tumor. Clin Imaging. 2013; 37(5):962-4. DOI: 10.1016/j.clinimag.2013.05.005. View

12.

Tsuruoka M, Inoue J, Kakazu E, Ninomiya M, Iwata T, Sano A . Methotrexate-associated Lymphoproliferative Disorder in the Liver Resembling Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Intern Med. 2020; 59(18):2255-2260. PMC: 7578598. DOI: 10.2169/internalmedicine.4787-20. View

13.

Miyagawa K, Shibata M, Noguchi H, Hayashi T, Oe S, Hiura M . Methotrexate-related primary hepatic lymphoma in a patient with rheumatoid arthritis. Intern Med. 2015; 54(4):401-5. DOI: 10.2169/internalmedicine.54.3361. View

14.

Tokuhira M, Tamaru J, Kizaki M . Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop. 2019; 59(2):72-92. PMC: 6661962. DOI: 10.3960/jslrt.19007. View

15.

Harigai M . Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective. Mod Rheumatol. 2017; 28(1):1-8. DOI: 10.1080/14397595.2017.1352477. View

16.

Omameuda T, Miyato H, Sata N, Lefor A . Primary hepatic methotrexate-associated lymphoproliferative disorder associated with Epstein-Barr virus reactivation and accompanied by spontaneous necrosis: A case report. Medicine (Baltimore). 2022; 101(47):e31993. PMC: 9705001. DOI: 10.1097/MD.0000000000031993. View

17.

Kuramoto N, Saito S, Fujii T, Kaneko Y, Saito R, Tanaka M . Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case-control study. Mod Rheumatol. 2021; 32(1):24-31. DOI: 10.1080/14397595.2021.1879362. View

18.

Soubrier M, Arrestier S, Bouloudian S, Dubost J, Ristori J . Epstein-Barr virus infection associated hepatic lymphoma in a patient treated with methotrexate for rheumatoid arthritis. Joint Bone Spine. 2006; 73(2):218-9. DOI: 10.1016/j.jbspin.2005.06.005. View

19.

Hatayama Y, Sugiyama H, Murakami D, Oura H, Shima Y, Shirato M . Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy. J Med Cases. 2023; 14(8):282-288. PMC: 10482596. DOI: 10.14740/jmc4135. View

20.

Watanabe S, Takahashi K, Funakoshi K, Terai S . Methotrexate-Associated Lymphoproliferative Disorder: A Rare Case of Large Liver Tumors. Hepatology. 2019; 70(2):748-750. DOI: 10.1002/hep.30606. View